Cover Image
Market Research Report
Product code 
1097662

Gene Therapy Market By Vector Type, By Therapy, By Gene Type, By Application : Global Opportunity Analysis and Industry Forecast, 2020-2030

Published: | Allied Market Research | 262 Pages | Delivery time: 2-3 business days

Price

Back to Top
Gene Therapy Market By Vector Type, By Therapy, By Gene Type, By Application : Global Opportunity Analysis and Industry Forecast, 2020-2030
Published: April 1, 2022
Allied Market Research
Content info: 262 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

Genes are composed of DNA that contains the necessary information to produce proteins that are vital for the human body to function optimally. Few gene mutations are expected to disrupt protein production or not develop these proteins at all, causing genetic disorders. Gene therapy works by repairing, dis-activating ("turning-off"), or replacing dysfunctional genes that cause diseases. It can be used for drug development with the right target and approach. In addition, it can address the root cause of severe disease. For certain disorders, where known genetic mutations lead to deficient or non-functional protein production, gene therapy can "fix" the underlying defect and/or provide a path for the production of functional protein. There are two types of gene therapy based on the location of the target gene on the chromosome includes somatic gene therapy & germ line gene therapy. It can be applied for the treatment of several diseases, such as Parkinson's, hemophilia, cystic fibrosis, Alzheimer's, brain tumors, cancer, AIDS, SCID, and others.

An increase in funding for R&D activities pertaining to gene therapy and growth in awareness regarding gene therapy drives the global market growth. In addition, an increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in the prevalence of cancer fuel the growth of the market. However, the high cost associated with the treatment and unwanted immune responses is expected to hamper the market growth in upcoming years.

The gene therapy market is segmented on the basis of vector type, gene type, application, and region. On the basis of vector type, it is bifurcated into viral and non-viral vectors. The viral vector segment is further segmented into retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, herpes simplex viruses, poxvirus, vaccinia virus, and others. The non-viral vector segment is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. By therapy type, the market is classified into ex vivo therapy and in vivo therapy. By gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others.

By application, it is divided into oncological disorders, rare diseases, neurological disorders, and other diseases. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

  • The key players operating in the global gene therapy market include Novartis AG, Gilead Sciences., Jazz Pharmaceuticals, Orchard Therapeutics., Bristol-Myers Squibb., Amgen Inc., Shenzhen SiBiono Genentech, Shanghai Sunway Biotech Co., Ltd., Adaptimmune Therapeutics plc, Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Amgen Inc., Astellas Therapeutics, Inc., Bluebird Bio, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., REGENXBIO Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc., Merck and Co Inc., and Dendron Corporation.
  • Key Benefits For Stakeholders
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gene therapy market analysis from 2020 to 2030 to identify the prevailing gene therapy market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the gene therapy market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global gene therapy market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Vector Type

  • Viral Vector
  • Non Viral Vector

By Therapy

  • In Vivo Therapy
  • Ex Vivo Therapy

By Gene Type

  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide
  • Deficiency
  • Growth factors
  • Receptors
  • Others

By Application

  • Oncological Disorders
  • Rare Diseases
  • Neurological Disorders
  • Other Diseases

By Region

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
  • Key Market Players
    • Novartis AG
    • Gilead Sciences.
    • Jazz Pharmaceuticals
    • Orchard Therapeutics.
    • Bristol-Myers Squibb.
    • Amgen Inc.
    • Shenzhen SiBiono GeneTech
    • Shanghai Sunway Biotech Co. Ltd.
    • Adaptimmune Therapeutics plc
    • Adverum Biotechnologies Inc.
    • Abeona Therapeutics Inc.
    • Applied Genetic Technologies Corporation
    • Astellas Therapeutics Inc.
    • Bluebird Bio, Inc.
    • CRISPR Therapeutics AG
    • Intellia Therapeutics, Inc.
    • REGENXBIO Inc.
    • Sangamo Therapeutics, Inc.
    • Uniqure N. V., Voyager Therapeutics, Inc.
    • Merck and Co Inc.
    • Dendron Corporation
Product Code: A02506

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GENE THERAPY MARKET, BY VECTOR TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Viral Vector
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Non Viral Vector
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: GENE THERAPY MARKET, BY THERAPY

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 In Vivo Therapy
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Ex Vivo Therapy
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: GENE THERAPY MARKET, BY GENE TYPE

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Antigen
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Cytokine
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Tumor Suppressor
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country
  • 6.5 Suicide
    • 6.5.1 Key market trends, growth factors and opportunities
    • 6.5.2 Market size and forecast, by region
    • 6.5.3 Market analysis by country
  • 6.6 Deficiency
    • 6.6.1 Key market trends, growth factors and opportunities
    • 6.6.2 Market size and forecast, by region
    • 6.6.3 Market analysis by country
  • 6.7 Growth factors
    • 6.7.1 Key market trends, growth factors and opportunities
    • 6.7.2 Market size and forecast, by region
    • 6.7.3 Market analysis by country
  • 6.8 Receptors
    • 6.8.1 Key market trends, growth factors and opportunities
    • 6.8.2 Market size and forecast, by region
    • 6.8.3 Market analysis by country
  • 6.9 Others
    • 6.9.1 Key market trends, growth factors and opportunities
    • 6.9.2 Market size and forecast, by region
    • 6.9.3 Market analysis by country

CHAPTER 7: GENE THERAPY MARKET, BY APPLICATION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Oncological Disorders
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market analysis by country
  • 7.3 Rare Diseases
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market analysis by country
  • 7.4 Neurological Disorders
    • 7.4.1 Key market trends, growth factors and opportunities
    • 7.4.2 Market size and forecast, by region
    • 7.4.3 Market analysis by country
  • 7.5 Other Diseases
    • 7.5.1 Key market trends, growth factors and opportunities
    • 7.5.2 Market size and forecast, by region
    • 7.5.3 Market analysis by country

CHAPTER 8: GENE THERAPY MARKET, BY REGION

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 North America
    • 8.2.1 Key trends and opportunities
    • 8.2.2 North America Market size and forecast, by Vector Type
    • 8.2.3 North America Market size and forecast, by Therapy
    • 8.2.4 North America Market size and forecast, by Gene Type
    • 8.2.5 North America Market size and forecast, by Application
    • 8.2.6 North America Market size and forecast, by country
      • 8.2.6.1 U.S.
      • 8.2.6.1.1 Market size and forecast, by Vector Type
      • 8.2.6.1.2 Market size and forecast, by Therapy
      • 8.2.6.1.3 Market size and forecast, by Gene Type
      • 8.2.6.1.4 Market size and forecast, by Application
      • 8.2.6.2 Canada
      • 8.2.6.2.1 Market size and forecast, by Vector Type
      • 8.2.6.2.2 Market size and forecast, by Therapy
      • 8.2.6.2.3 Market size and forecast, by Gene Type
      • 8.2.6.2.4 Market size and forecast, by Application
      • 8.2.6.3 Mexico
      • 8.2.6.3.1 Market size and forecast, by Vector Type
      • 8.2.6.3.2 Market size and forecast, by Therapy
      • 8.2.6.3.3 Market size and forecast, by Gene Type
      • 8.2.6.3.4 Market size and forecast, by Application
  • 8.3 Europe
    • 8.3.1 Key trends and opportunities
    • 8.3.2 Europe Market size and forecast, by Vector Type
    • 8.3.3 Europe Market size and forecast, by Therapy
    • 8.3.4 Europe Market size and forecast, by Gene Type
    • 8.3.5 Europe Market size and forecast, by Application
    • 8.3.6 Europe Market size and forecast, by country
      • 8.3.6.1 Germany
      • 8.3.6.1.1 Market size and forecast, by Vector Type
      • 8.3.6.1.2 Market size and forecast, by Therapy
      • 8.3.6.1.3 Market size and forecast, by Gene Type
      • 8.3.6.1.4 Market size and forecast, by Application
      • 8.3.6.2 France
      • 8.3.6.2.1 Market size and forecast, by Vector Type
      • 8.3.6.2.2 Market size and forecast, by Therapy
      • 8.3.6.2.3 Market size and forecast, by Gene Type
      • 8.3.6.2.4 Market size and forecast, by Application
      • 8.3.6.3 U.K.
      • 8.3.6.3.1 Market size and forecast, by Vector Type
      • 8.3.6.3.2 Market size and forecast, by Therapy
      • 8.3.6.3.3 Market size and forecast, by Gene Type
      • 8.3.6.3.4 Market size and forecast, by Application
      • 8.3.6.4 Italy
      • 8.3.6.4.1 Market size and forecast, by Vector Type
      • 8.3.6.4.2 Market size and forecast, by Therapy
      • 8.3.6.4.3 Market size and forecast, by Gene Type
      • 8.3.6.4.4 Market size and forecast, by Application
      • 8.3.6.5 Spain
      • 8.3.6.5.1 Market size and forecast, by Vector Type
      • 8.3.6.5.2 Market size and forecast, by Therapy
      • 8.3.6.5.3 Market size and forecast, by Gene Type
      • 8.3.6.5.4 Market size and forecast, by Application
      • 8.3.6.6 Rest of Europe
      • 8.3.6.6.1 Market size and forecast, by Vector Type
      • 8.3.6.6.2 Market size and forecast, by Therapy
      • 8.3.6.6.3 Market size and forecast, by Gene Type
      • 8.3.6.6.4 Market size and forecast, by Application
  • 8.4 Asia-Pacific
    • 8.4.1 Key trends and opportunities
    • 8.4.2 Asia-Pacific Market size and forecast, by Vector Type
    • 8.4.3 Asia-Pacific Market size and forecast, by Therapy
    • 8.4.4 Asia-Pacific Market size and forecast, by Gene Type
    • 8.4.5 Asia-Pacific Market size and forecast, by Application
    • 8.4.6 Asia-Pacific Market size and forecast, by country
      • 8.4.6.1 Japan
      • 8.4.6.1.1 Market size and forecast, by Vector Type
      • 8.4.6.1.2 Market size and forecast, by Therapy
      • 8.4.6.1.3 Market size and forecast, by Gene Type
      • 8.4.6.1.4 Market size and forecast, by Application
      • 8.4.6.2 China
      • 8.4.6.2.1 Market size and forecast, by Vector Type
      • 8.4.6.2.2 Market size and forecast, by Therapy
      • 8.4.6.2.3 Market size and forecast, by Gene Type
      • 8.4.6.2.4 Market size and forecast, by Application
      • 8.4.6.3 Australia
      • 8.4.6.3.1 Market size and forecast, by Vector Type
      • 8.4.6.3.2 Market size and forecast, by Therapy
      • 8.4.6.3.3 Market size and forecast, by Gene Type
      • 8.4.6.3.4 Market size and forecast, by Application
      • 8.4.6.4 India
      • 8.4.6.4.1 Market size and forecast, by Vector Type
      • 8.4.6.4.2 Market size and forecast, by Therapy
      • 8.4.6.4.3 Market size and forecast, by Gene Type
      • 8.4.6.4.4 Market size and forecast, by Application
      • 8.4.6.5 South Korea
      • 8.4.6.5.1 Market size and forecast, by Vector Type
      • 8.4.6.5.2 Market size and forecast, by Therapy
      • 8.4.6.5.3 Market size and forecast, by Gene Type
      • 8.4.6.5.4 Market size and forecast, by Application
      • 8.4.6.6 Rest Of Asia Pacific
      • 8.4.6.6.1 Market size and forecast, by Vector Type
      • 8.4.6.6.2 Market size and forecast, by Therapy
      • 8.4.6.6.3 Market size and forecast, by Gene Type
      • 8.4.6.6.4 Market size and forecast, by Application
  • 8.5 LAMEA
    • 8.5.1 Key trends and opportunities
    • 8.5.2 LAMEA Market size and forecast, by Vector Type
    • 8.5.3 LAMEA Market size and forecast, by Therapy
    • 8.5.4 LAMEA Market size and forecast, by Gene Type
    • 8.5.5 LAMEA Market size and forecast, by Application
    • 8.5.6 LAMEA Market size and forecast, by country
      • 8.5.6.1 Brazil
      • 8.5.6.1.1 Market size and forecast, by Vector Type
      • 8.5.6.1.2 Market size and forecast, by Therapy
      • 8.5.6.1.3 Market size and forecast, by Gene Type
      • 8.5.6.1.4 Market size and forecast, by Application
      • 8.5.6.2 Saudi Arabia
      • 8.5.6.2.1 Market size and forecast, by Vector Type
      • 8.5.6.2.2 Market size and forecast, by Therapy
      • 8.5.6.2.3 Market size and forecast, by Gene Type
      • 8.5.6.2.4 Market size and forecast, by Application
      • 8.5.6.3 South Africa
      • 8.5.6.3.1 Market size and forecast, by Vector Type
      • 8.5.6.3.2 Market size and forecast, by Therapy
      • 8.5.6.3.3 Market size and forecast, by Gene Type
      • 8.5.6.3.4 Market size and forecast, by Application
      • 8.5.6.4 Rest of LAMEA
      • 8.5.6.4.1 Market size and forecast, by Vector Type
      • 8.5.6.4.2 Market size and forecast, by Therapy
      • 8.5.6.4.3 Market size and forecast, by Gene Type
      • 8.5.6.4.4 Market size and forecast, by Application

CHAPTER 9: COMPANY LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

10.1

    • 10.1.1 Company overview
    • 10.1.2 Company snapshot
    • 10.1.3 Operating business segments
    • 10.1.4 Product portfolio
    • 10.1.5 Business performance
    • 10.1.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, 2020-2030,($MILLION)
  • TABLE 2. GENE THERAPY MARKET REVENUE, FOR VIRAL VECTOR, BY REGION , 2020-2030,($MILLION)
  • TABLE 3. GENE THERAPY MARKET VIRAL VECTOR BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 4. GENE THERAPY MARKET REVENUE, FOR NON VIRAL VECTOR, BY REGION , 2020-2030,($MILLION)
  • TABLE 5. GENE THERAPY MARKET NON VIRAL VECTOR BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 6. GLOBAL GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
  • TABLE 7. GENE THERAPY MARKET REVENUE, FOR IN VIVO THERAPY, BY REGION , 2020-2030,($MILLION)
  • TABLE 8. GENE THERAPY MARKET IN VIVO THERAPY BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 9. GENE THERAPY MARKET REVENUE, FOR EX VIVO THERAPY, BY REGION , 2020-2030,($MILLION)
  • TABLE 10. GENE THERAPY MARKET EX VIVO THERAPY BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 11. GLOBAL GENE THERAPY MARKET, BY GENE TYPE, 2020-2030,($MILLION)
  • TABLE 12. GENE THERAPY MARKET REVENUE, FOR ANTIGEN, BY REGION , 2020-2030,($MILLION)
  • TABLE 13. GENE THERAPY MARKET ANTIGEN BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 14. GENE THERAPY MARKET REVENUE, FOR CYTOKINE, BY REGION , 2020-2030,($MILLION)
  • TABLE 15. GENE THERAPY MARKET CYTOKINE BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 16. GENE THERAPY MARKET REVENUE, FOR TUMOR SUPPRESSOR, BY REGION , 2020-2030,($MILLION)
  • TABLE 17. GENE THERAPY MARKET TUMOR SUPPRESSOR BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 18. GENE THERAPY MARKET REVENUE, FOR SUICIDE, BY REGION , 2020-2030,($MILLION)
  • TABLE 19. GENE THERAPY MARKET SUICIDE BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 20. GENE THERAPY MARKET REVENUE, FOR DEFICIENCY, BY REGION , 2020-2030,($MILLION)
  • TABLE 21. GENE THERAPY MARKET DEFICIENCY BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 22. GENE THERAPY MARKET REVENUE, FOR GROWTH FACTORS, BY REGION , 2020-2030,($MILLION)
  • TABLE 23. GENE THERAPY MARKET GROWTH FACTORS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 24. GENE THERAPY MARKET REVENUE, FOR RECEPTORS, BY REGION , 2020-2030,($MILLION)
  • TABLE 25. GENE THERAPY MARKET RECEPTORS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 26. GENE THERAPY MARKET REVENUE, FOR OTHERS, BY REGION , 2020-2030,($MILLION)
  • TABLE 27. GENE THERAPY MARKET OTHERS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 28. GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
  • TABLE 29. GENE THERAPY MARKET REVENUE, FOR ONCOLOGICAL DISORDERS, BY REGION , 2020-2030,($MILLION)
  • TABLE 30. GENE THERAPY MARKET ONCOLOGICAL DISORDERS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 31. GENE THERAPY MARKET REVENUE, FOR RARE DISEASES, BY REGION , 2020-2030,($MILLION)
  • TABLE 32. GENE THERAPY MARKET RARE DISEASES BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 33. GENE THERAPY MARKET REVENUE, FOR NEUROLOGICAL DISORDERS, BY REGION , 2020-2030,($MILLION)
  • TABLE 34. GENE THERAPY MARKET NEUROLOGICAL DISORDERS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 35. GENE THERAPY MARKET REVENUE, FOR OTHER DISEASES, BY REGION , 2020-2030,($MILLION)
  • TABLE 36. GENE THERAPY MARKET OTHER DISEASES BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 37. GENE THERAPY MARKET, BY REGION, 2020-2030,($MILLION)
  • TABLE 38. NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2020-2030,($MILLION)
  • TABLE 39. NORTH AMERICA GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
  • TABLE 40. NORTH AMERICA GENE THERAPY MARKET, BY GENE TYPE, 2020-2030,($MILLION)
  • TABLE 41. NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
  • TABLE 42. NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 43. U.S. GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 44. U.S. GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 45. U.S. GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 46. U.S. GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 47. CANADA GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 48. CANADA GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 49. CANADA GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 50. CANADA GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 51. MEXICO GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 52. MEXICO GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 53. MEXICO GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 54. MEXICO GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 55. EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2020-2030,($MILLION)
  • TABLE 56. EUROPE GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
  • TABLE 57. EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2020-2030,($MILLION)
  • TABLE 58. EUROPE GENE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
  • TABLE 59. EUROPE GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 60. GERMANY GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 61. GERMANY GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 62. GERMANY GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 63. GERMANY GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 64. FRANCE GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 65. FRANCE GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 66. FRANCE GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 67. FRANCE GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 68. U.K. GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 69. U.K. GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 70. U.K. GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 71. U.K. GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 72. ITALY GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 73. ITALY GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 74. ITALY GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 75. ITALY GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 76. SPAIN GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 77. SPAIN GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 78. SPAIN GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 79. SPAIN GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 80. REST OF EUROPE GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 81. REST OF EUROPE GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 82. REST OF EUROPE GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 83. REST OF EUROPE GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 84. ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2020-2030,($MILLION)
  • TABLE 85. ASIA-PACIFIC GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
  • TABLE 86. ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2020-2030,($MILLION)
  • TABLE 87. ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
  • TABLE 88. ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 89. JAPAN GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 90. JAPAN GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 91. JAPAN GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 92. JAPAN GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 93. CHINA GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 94. CHINA GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 95. CHINA GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 96. CHINA GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 97. AUSTRALIA GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 98. AUSTRALIA GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 99. AUSTRALIA GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 100. AUSTRALIA GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 101. INDIA GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 102. INDIA GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 103. INDIA GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 104. INDIA GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 105. SOUTH KOREA GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 106. SOUTH KOREA GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 107. SOUTH KOREA GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 108. SOUTH KOREA GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 111. REST OF ASIA PACIFIC GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 112. REST OF ASIA PACIFIC GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 113. LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2020-2030,($MILLION)
  • TABLE 114. LAMEA GENE THERAPY MARKET, BY THERAPY, 2020-2030,($MILLION)
  • TABLE 115. LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2020-2030,($MILLION)
  • TABLE 116. LAMEA GENE THERAPY MARKET, BY APPLICATION, 2020-2030,($MILLION)
  • TABLE 117. LAMEA GENE THERAPY MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 118. BRAZIL GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 119. BRAZIL GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 120. BRAZIL GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 121. BRAZIL GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 122. SAUDI ARABIA GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 123. SAUDI ARABIA GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 124. SAUDI ARABIA GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 125. SAUDI ARABIA GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 126. SOUTH AFRICA GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 127. SOUTH AFRICA GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 128. SOUTH AFRICA GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 129. SOUTH AFRICA GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 130. REST OF LAMEA GENE THERAPY MARKET BY VECTOR TYPE 2020-2030,($MILLION)
  • TABLE 131. REST OF LAMEA GENE THERAPY MARKET BY THERAPY 2020-2030,($MILLION)
  • TABLE 132. REST OF LAMEA GENE THERAPY MARKET BY GENE TYPE 2020-2030,($MILLION)
  • TABLE 133. REST OF LAMEA GENE THERAPY MARKET BY APPLICATION 2020-2030,($MILLION)
  • TABLE 134.: COMPANY SNAPSHOT
  • TABLE 135.: OPERATING SEGMENTS
  • TABLE 136.: PRODUCT PORTFOLIO
  • TABLE 137.: NET SALES,
  • TABLE 138.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.GENE THERAPY MARKET SEGMENTATION
  • FIGURE 2.GENE THERAPY MARKET,2020-2030
  • FIGURE 3.GENE THERAPY MARKET,2020-2030
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.GENE THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11.GENE THERAPY MARKET,BY VECTOR TYPE,2020(%)
  • FIGURE 12.COMPARATIVE SHARE ANALYSIS OF VIRAL VECTOR GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF NON VIRAL VECTOR GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 14.GENE THERAPY MARKET,BY THERAPY,2020(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF IN VIVO THERAPY GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF EX VIVO THERAPY GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 17.GENE THERAPY MARKET,BY GENE TYPE,2020(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ANTIGEN GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CYTOKINE GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF TUMOR SUPPRESSOR GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF SUICIDE GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DEFICIENCY GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF GROWTH FACTORS GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF RECEPTORS GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 26.GENE THERAPY MARKET,BY APPLICATION,2020(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF ONCOLOGICAL DISORDERS GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 28.COMPARATIVE SHARE ANALYSIS OF RARE DISEASES GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF NEUROLOGICAL DISORDERS GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF OTHER DISEASES GENE THERAPY MARKET,2020-2030(%)
  • FIGURE 31.GENE THERAPY MARKET BY REGION,2020
  • FIGURE 32.U.S. GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 33.CANADA GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 34.MEXICO GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 35.GERMANY GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 36.FRANCE GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 37.U.K. GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 38.ITALY GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 39.SPAIN GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 40.REST OF EUROPE GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 41.JAPAN GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 42.CHINA GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 43.AUSTRALIA GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 44.INDIA GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 45.SOUTH KOREA GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 46.REST OF ASIA PACIFIC GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 47.BRAZIL GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 48.SAUDI ARABIA GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 49.SOUTH AFRICA GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 50.REST OF LAMEA GENE THERAPY MARKET,2020-2030($MILLION)
  • FIGURE 51. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 52. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 53. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 54.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 55.COMPETITIVE DASHBOARD
  • FIGURE 56.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 57..: NET SALES ,($MILLION)